Trial Profile
Clinical Study of Plasmodium Immunotherapy for Advanced Non-small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Plasmodium immunotherapy CAS Lamvac Biotech (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 24 Dec 2017 Planned number of patients changed from 80 to 30.
- 17 Jun 2016 New trial record